Amal Therapeutics

Amal Therapeutics is a biotech company, which engages in the research and development of therapeutic vaccines in oncology. The Company uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines.

TypeSubsidiary
Parent CompanyBoehringer Ingelheim
HQGenève, CH
Websiteamaltherapeutics.com
Cybersecurity ratingAMore
Amal Therapeutics is headquartered in Genève, CH

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Amal Therapeutics

Laurence de Schoulepnikoff

Laurence de Schoulepnikoff

COO
Madiha Derouazi

Madiha Derouazi

Founder and CEO
Greg Elson

Greg Elson

VP, Manufacturing
Elodie Belnoue

Elodie Belnoue

Head of Research in Vivo
Jean-Francois Mayol

Jean-Francois Mayol

Head of Translational Research
Thomas Bogenrieder

Thomas Bogenrieder

Chief Clinical Officer
Show more

Amal Therapeutics Office Locations

Amal Therapeutics has an office in Genève
Genève, CH (HQ)
La Tulipe 64 Avenue de la Roseraie
Show all (1)

Amal Therapeutics Financials and Metrics

Summary Metrics

Total Funding

$45.5 m

Investors

In total, Amal Therapeutics had raised $45.5 m. Amal Therapeutics is a subsidiary of Boehringer Ingelheim

Amal Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Amal Therapeutics Online and Social Media Presence

Embed Graph

Amal Therapeutics Blogs

AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website

AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research …

AMAL Therapeutics to publish in vivo research outcomes in Frontiers in Immunology

AMAL Therapeutics to publish in vivo research outcomes in Frontiers in Immunology Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website. Altogether, the results pre…

AMAL Therapeutics to publish R&D outcomes in Cancers

AMAL Therapeutics to publish R&D outcomes in Cancers Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the f…

CIMT Annual Meeting 2020

CIMT Annual Meeting 2020 May 5-7, 2020 / Mainz / Germany Jean-François Mayol attending

AACR Annual Meeting 2020

AACR Annual Meeting 2020 April 24-29, 2020 / San Diego / USA Madiha Derouazi presenting

ESMO Immuno-Oncology Congress 2019

ESMO Immuno-Oncology Congress 2019 December 11–14, 2019 / Geneva / Switzerland AMAL Team attending
Show more

Amal Therapeutics Frequently Asked Questions

  • Who are Amal Therapeutics key executives?

    Amal Therapeutics's key executives are Laurence de Schoulepnikoff, Madiha Derouazi and Greg Elson.

  • How many employees does Amal Therapeutics have?

    Amal Therapeutics has 22 employees.

  • Who are Amal Therapeutics competitors?

    Competitors of Amal Therapeutics include Eutilex, Foghorn Therapeutics and Reflexion Medical.

  • Where is Amal Therapeutics headquarters?

    Amal Therapeutics headquarters is located at La Tulipe 64 Avenue de la Roseraie, Genève.

  • Where are Amal Therapeutics offices?

    Amal Therapeutics has an office in Genève.

  • How many offices does Amal Therapeutics have?

    Amal Therapeutics has 1 office.